Finding
US Supreme Court Rejects Purdue’s Multibillion-Dollar Opioid Pact
US Supreme Court, Purdue Pharma, Opioid Settlement, Sackler Family, Bankruptcy, Opioid Crisis
FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma
EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment
Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership
Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership
Sarepta Therapeutics: Next Steps After Full FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Sarepta Therapeutics, Duchenne muscular dystrophy, gene therapy, FDA approval, Elevidys, microdystrophin, ambulatory patients, non-ambulatory patients, pipeline development, rare diseases, genetic medicine.
Three Ways to Solve the Patient Support Paradox
Patient Support Paradox, Patient Experience, Healthcare, Patient Flow, Patient Engagement
Novo Nordisk Wins Approval in China for GLP-1 Obesity Drug Wegovy
Novo Nordisk, Wegovy, GLP-1, Obesity, China, Weight Loss, Semaglutide, Ozempic
Vertex Announces Positive Results for VX-880 in Type 1 Diabetes Treatment
Vertex Pharmaceuticals, VX-880, Type 1 Diabetes, Stem Cell Therapy, Insulin Independence, Severe Hypoglycemic Events
FDA Expands Approval of Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy to Include Older Boys and Non-Ambulatory Patients
FDA, Sarepta, Duchenne Muscular Dystrophy, Gene Therapy, Elevidys, Ambulatory, Non-Ambulatory, Expanded Approval
Silence’s siRNA therapy maintains Lp(a) lowering in cardiovascular study
Lp(a ), RNA, Small Interfering, Cardiovascular Diseases
Taysha Gene Therapies Announces Positive Results for TSHA-102 in Rett Syndrome Trials
Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Motor Skills, Communication, Autonomic Function, Seizures